RxDoctor Payments Data

Salma Farukhi, MD

Family Medicine · Orange, CANPI 1982966883

Payments from drug & device makers

$963in general payments, 2019–2025

Across 37 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$493
  • Amgen$121
  • AstraZeneca$85
  • Dexcom, Inc.$61
  • Pfizer$51
  • Johnson & Johnson$43
  • plus $109 from 4 others

What the payments were for

  • Food & beverage$963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC17$493
Amgen5$121
AstraZeneca4$85
Dexcom, Inc.2$61
Pfizer2$51
Johnson & Johnson2$43
Sanofi-aventis U.S. LLC1$39
Exact Sciences1$25
GSK2$24
CMP Pharma, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$963 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$323,157
Medicare patients
467
Services billed
3,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin298$198,442
EliquisApixaban459$156,141
XifaxanRifaximin27$85,551
OzempicSemaglutide68$70,403
VelphoroSucroferric Oxyhydroxide14$47,580
MounjaroTirzepatide54$47,155
RybelsusSemaglutide20$29,279
XareltoRivaroxaban31$28,694
LinzessLinaclotide42$25,949
JanuviaSitagliptin Phosphate36$25,613
LokelmaSodium Zirconium Cyclosilicate25$21,115
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$18,408
TrulicityDulaglutide23$17,743
SantylCollagenase Clostridium Hist.17$16,013
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$14,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$156,141459 claims
Lilly USA, LLCMounjaro, Trulicity$493$64,89877 claims
AstraZenecaLokelma, Breztri Aerosphere$85$35,94947 claims
Johnson & JohnsonXarelto$43$28,69431 claims
GSKTrelegy Ellipta$24$9,75415 claims
AmgenEpogen$121$8,85215 claims
Sanofi-aventis U.S. LLCLantus$39$4,86558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →